title: Changes in gamma-secretase activity and specificity caused by the introduction of consensus aspartyl protease active motif in Presenilin 1.
abstract: Presenilin (PS1 or PS2) is an essential component of the active gamma-secretase complex that liberates the Abeta peptides from amyloid precursor protein (APP). PS1 is regarded as an atypical aspartyl protease harboring two essential aspartic acids in the context of the sequence D257LV and D385FI, respectively, rather than the typical DTG...DTG catalytic motif of classical aspartyl proteases. In the present studies, we introduced the sequence DTG in PS1 at and around the catalytic D257 and D385 residues to generate three PS1 mutants: D257TG, D385TG, and the double-mutant D257TG/D385TG. The effects of these changes on the gamma-secretase activity in the presence or absence of gamma-secretase inhibitors and modulators were investigated. The results showed that PS1 mutants having D385TG robustly enhanced Abeta42 production compared to the wild type (wt), and were more sensitive than wt to inhibition by a classical aspartyl protease transition state mimic, and fenchylamine, a sulfonamide derivative. Unlike wt PS1 and some of its clinical mutants, all three PS1 artificial mutants decreased cleavage of Notch S3-site, suggesting that these artificial mutations may trigger conformational changes at the substrate docking and catalytic site that cause alteration of substrate specificity and inhibition pattern. Consistent with this notion, we have found that NSAID enzymatic inhibitors of COX, known modulators of the gamma-secretase activity, cause PS1 mutants containing D385TG to produce higher levels of both Abeta38 and Abeta42, but to reduce levels of Abeta39, showing a pattern of Abeta formation different from that observed with wild type PS1 and its clinical mutants. This study provides an important structural clue for the rational design of drugs to inhibit processing of APP at the gamma-site without interfering with Notch processing.
authors.affiliation: Global Research and Development, Pfizer Inc, Kalamazoo, MI 49001, USA. alfredo.tomasselli@pfizer.com.
authors.forename: Donald B
authors.initials: DB
authors.lastname: Carter
authors.forename: Edwige
authors.initials: E
authors.lastname: Dunn
authors.forename: Adele M
authors.initials: AM
authors.lastname: Pauley
authors.forename: Denise D
authors.initials: DD
authors.lastname: McKinley
authors.forename: Timothy J
authors.initials: TJ
authors.lastname: Fleck
authors.forename: Brenda R
authors.initials: BR
authors.lastname: Ellerbrook
authors.forename: Nancy C
authors.initials: NC
authors.lastname: Stratman
authors.forename: Xiangdong
authors.initials: X
authors.lastname: Zhou
authors.forename: Carol S
authors.initials: CS
authors.lastname: Himes
authors.forename: Jeffrey S
authors.initials: JS
authors.lastname: Nye
authors.forename: Alfredo
authors.initials: A
authors.lastname: Tomasselli
authors.forename: Riqiang
authors.initials: R
authors.lastname: Yan